TGFB1 and osteogenesis imperfecta: Similarly, pharmacologic inhibition of TGFbeta with a neutralizing antibody leads to increased bone mass and stronger bones in mice with osteogenesis imperfecta, a disease that is characterized by weak and fragile bones [19].